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TITLE RUNNING HEAD. Lamellarin D – PEG conjugates. 
 
ABSTRACT.  
Herein is reported the design and synthesis of poly(ethylene glycol) derivatives of 
Lamellarin D with the aim of modulating their physicochemical properties, and 
improving the biological activity. Mono-, di- and tri-PEG conjugates with improved 
solubility were obtained in 18-57% overall yields from the corresponding partially 
protected phenolic derivatives of Lamellarin D. Conjugates 1-9 were tested in a panel of 
three human tumor cell lines (MDA-MB-231 breast, A-549 lung and HT-29 colon) to 
evaluate their cytotoxicity. Several compounds exhibited enhanced cellular 
internalization, and more than 85% of the derivatives showed a lower GI50 than Lam-D. 
Furthermore, cell cycle arrest at G2 phase, and apoptotic cell-death pathways were 
determined for Lamellarin D and these derivatives.  
 
 
KEYWORDS. Lamellarin D, anti-cancer drugs, polyethylene glycol, bioconjugation, 
polymeric prodrugs. 
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INTRODUCTION 
Compounds with a good therapeutic profile often do not reach the drug market 
because they show poor pharmacokinetics, mainly due to poor solubility. Attachment of 
well-defined, water-soluble, biocompatible, non-toxic, and non-immunogenic polymeric 
systems to drug candidates can overcome this limitation. Furthermore, these chemical 
modifications can significantly improve tumor targeting, in addition to therapeutic 
efficacy, by EPR1 effect of the drug in tumor tissue. Advances in this field require 
robust and reliable chemical strategies for the preparation of such derivatives of key 
pharmacological lead compounds, because very often the polymeric backbone should be 
incorporated to the chemical structure in the middle of the synthetic strategy.  
Lam-D (1-6) (1) is a marine alkaloid with a wide range of biological activities, such 
as anti-proliferative activity against various tumor cell lines in the low nanomolar 
concentration. Lam-D inhibits the Topo I (3), thereby disrupting the  potential of 
mitochondrial transmembrane (4) which promotes apoptosis (7). The conjugation of 
water-soluble biocompatible polymers to low molecular weight anti-cancer drugs has 
been reported to enhance the solubility of the drugs, enhance their accumulation in 
tumors, and prolong their retention in the circulatory system, thereby improving the 
drugs’ pharmacodynamics and pharmacokinetics (8, 9). Notwithstanding, further 
controlled drug delivery by means of a readily hydrolyzable conjugation bond is 
required for the appropriate release of the bioactive drug (10). Therefore, modulation of 
biopolymers that bind drugs is of paramount importance for preclinical research and 
developments with new lead compounds (11). Recently, PEGylated compounds used in 
cancer therapy have been shown to promote the EPR effect (12, 13), raising the local 
concentration of drug accumulated in targeted solid tumors. It has been proposed that 
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this effect is caused by vascular leakage in the tumor and a reduction in the tumor’s 
lymphatic drainage (14).  
Our group sought to modulate the physicochemical properties of Lam-D by creating a 
series of mono-, di- and tri-PEG ester conjugates of this drug. Herein are described the 
syntheses using modified synthetic strategies of these conjugates, as well as their 
biological activity. 
EXPERIMENTAL PROCEDURES 
General Procedures and Product Characterization  
A) General Procedures for Cross-Coupling Reactions.  
A solution of bromide derivative 14 (1.0 mmol) in DMF (20 mL) was purged with Ar 
for 10 min, and boronate 12 (1.0 mmol), Pd(PPh3)4 (10%) and 2M K3PO4 (3.0 mmol) 
were then added. The reaction mixture was stirred at 115 ºC, and then another portion of 
boronate 12 (2.0 mmol) was added dropwise using a syringe pump during the first hour 
of reaction. The solvent was removed and the residue was dissolved in EtOAc. The 
organic solution was washed with water and brine, dried, and concentrated to give a 
crude material, which was later purified by column chromatography on silica gel. 
Elution with hexane/EtOAc (75:25 to 60:40) gave 15a-c (69-77% yield). 
B) General Procedure for Oxidation. Synthesis of compounds 16. A mixture of 15 
(1.0 mmol) and DDQ (1.0 mmol) in dry CHCl3 (15 mL) was purged with Ar in a sealed 
vessel and heated in a microwave at 120 ºC for 10 min. The organic solution was 
washed with water and brine and then dried (MgSO4), filtered and evaporated in 
vacuum. The crude material was purified by column chromatography on silica gel. 
Elution with hexane/EtOAc (85:15 to 60:40) gave 16a-c (65-93% yield).  
C) General Method for Benzyloxy Removal  
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Pd/C (10%) was added to a solution of 16 (1.0 mmol) in MeOH (50 mL). The 
suspension was purged with H2 and stirred for 16 h. The reaction mixture was filtered 
through a Celite pad, which was washed with CH2Cl2. The solvent was removed under 
vacuum to provide the compounds 17a-c (yield 70-95%). 
D) General Method for Lactonization  
NaH (60% dispersion, 1.1 mmol/mmol free OH) was washed twice with dry THF and a 
solution of 17 (1 mmol) was added in THF (60 mL). The mixture was stirred for 3 h at 
r.t. The solvent was then removed under reduced pressure, and EtOAc was added to the 
residue. The organic solution was washed with saturated aq. NH4Cl, water, and brine, 
then dried and concentrated to provide the compounds 18a-c (86%-quant. yield). 
E) General Method for Esterification.  
EDC·HCl (4 mmol x free OH) was added in one solid portion to a solution of DMAP 
(0.6 mmol/mmol free OH in SM) PEG-COOH (4 mmol x free OH), and either Lam-D 
(15) or 18 (1 mmol) in dry CH2Cl2 (45 mL). The resulting solution was stirred at r.t. for 
3 h. The reaction mixture was diluted with CH2Cl2 and washed with sat. aq. NaHCO3  
and brine. The organic phase was dried over anhydrous MgSO4, and the solvent was 
removed under vacuum. The residue was directly purified on silica gel to provide 
compounds 8, 9, 19a-f (40%-quant. yield). 
F) General Method for Isopropoxy Deprotection.  
Anhydrous AlCl3 (1.3 equiv.) was added to a solution of compound 19 (1 mmol), in dry 
CH2Cl2 (1 mL). The mixture was sonicated for 10 min, quenched with sat. NH4Cl, then 
washed with water and brine. Compounds 19b and 19d were treated only with brine, 
and the aqueous solution was extracted with EtOAc. The organic extracts were dried 
and evaporated. The crude product was purified by flash chromatography to give 
compounds 2-7 (yield 19-59%). 
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Methyl 1-(4-benzyloxy-3-methoxyphenyl)-8-isopropoxy-9-methoxy-5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (13a)  
A solution of methyl 1-bromo-8-isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (543 mg, 1.4 mmol) in DMF (40 mL) was purged with Ar, 
and 2-(4-benzyloxy-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11a) 
(703 mg, 2.1 mmol), Pd(PPh3)4 (159 mg, 0.1 mmol) and 2M K2CO3 (2.8 mL, 5.5 mmol) 
were added. The reaction mixture was stirred at 125 ºC for 16 h. The solvent was 
removed after cooling to r.t. and the residue was dissolved in EtOAc. The organic 
solution was washed with water and brine, dried (MgSO4) and concentrated to give a 
crude material, which was later purified by column chromatography on silica gel. 
Elution with hexane/EtOAc (90:10 to 75:25) gave 13a (543 mg, 1.38 mmol) as a yellow 
oil (727 mg, quant.). IR (film) ν 1670, 1464, 1440, 1242. 1H NMR (CDCl3, 400 MHz) 
δ  1.37 (d, J = 6.0 Hz, 6H); 2.98 (t, J = 6.4 Hz, 2H); 3.31 (s, 3H, OMe); 3.84 (s, 3H, 
OMe); 3.85 (s, 3H, OMe); 4.52 (h, J = 6.0 Hz, 1H, OCH); 4.60 (t, J = 6.4 Hz, 2H); 5.19 
(s, 2H); 6.73 (s, 1H); 6.86 (s, 1H); 6.89 (s, 1H); 6.93 (dd, J = 8.0, 1.8 Hz, 1H); 6.96-7.00 
(m, 2H); 7.31 (d, J = 7.2 Hz, 1H); 7.35 (dd, J = 7.2, 7.2 Hz, 2H); 7.44 (d, J = 7.2 Hz, 
2H). 13C NMR (CDCl3, 50.3 MHz) δ 22.2 (2q); 29.0 (t); 42.6 (t); 51.1 (q); 55.4 (q); 56.1 
(q); 71.0 (t); 71.4 (d); 109.1 (d); 113.1 (d); 114.1 (d); 114.7 (d); 119.2 (d); 121.1 (s); 
121.47 (s); 121.54 (s); 125.6 (d); 127.1 (2d); 127.8 (d); 128.5 (2d); 129.8 (s); 137.2 (s); 
146.5 (s); 146.8 (s); 148.5 (s); 149.5 (s); 161.7 (s). MS (ESI) 528 (M+1, 100); 529 
(M+2, 37). HRMS m/z calcd .for C32H34NO6 528.2381, found 528.2373. 
Methyl 1-(4-benzyloxy-3-methoxyphenyl)-2-bromo-8-isopropoxy-9-methoxy-5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (14a)  
NBS (82 mg, 0.46 mmol) was added in one portion to a solution of 13a (245 mg, 0.46 
mmol) in THF (10 mL). The mixture was stirred at 70 ºC under Ar for 90 min. The 
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solvent was removed under reduced pressure. The residue was dissolved in CH2Cl2 and 
filtered through a pad of neutral alumina. 14a was obtained as a yellow oil (278 mg, 
99%). IR (film) ν  1693, 1462, 1112 cm-1. 1H NMR (CDCl3, 400 MHz) δ 1.35 (d, J = 
6.0 Hz, 6H); 2.98 (t, J = 6.4 Hz, 2H); 3.20 (s, 3H, OMe); 3.86 (s, 3H, OMe); 3.90 (s, 
3H, OMe); 4.51 (h, J = 6.0 Hz, 1H, OCH); 4.59 (t, J = 6.4 Hz, 2H); 5.20 (br, 2H); 6.54 
(s, 1H); 6.70 (s, 1H); 6.85-7.00 (m, 3H); 7.28-7.47 (m, 5H). 13C NMR (CDCl3, 100 
MHz) δ 22.0 (2q); 28.6 (t); 43.4 (t); 51.1 (q); 55.0 (q); 56.0 (q); 70.7 (t); 71.2 (d); 107.6 
(s); 108.9 (d); 113.0 (s); 113.7 (d); 113.9 (s); 114.3 (d); 114.5 (d); 119.1 (s); 122.2 (s); 
123.2 (d); 125.3 (s); 126.9 (2d); 127.6 (d); 128.4 (2d); 131.8 (s); 137.0 (s); 146.6 (s); 
147.3 (s); 148.3 (s); 149.4 (s); 161.1 (s). MS (ESI) 606 (MBr79+1, 100); 607 (MBr79+2, 
23); 608 (MBr81+1, 95). HRMS m/z calcd. for C32H33NO6Br 606.1486, found 606.1485. 
Methyl 2-(2,4-dibenzyloxy-5-methoxyphenyl)-8-isopropoxy-1-(4-isopropoxy-3-
methoxyphenyl)-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate 
(15a) 
Following the general procedure A and starting from 14b (16) (674 mg, 1.21 mmol) and 
2-(2,4-dibenzyloxy-5-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12b), a 
yellow oil (719 mg, 75%) was obtained. IR (film) ν 1691, 1254, 1212. 1H NMR 
(CDCl3, 200 MHz) δ 1.31 (d, J = 6.2 Hz, 6H); 1.35 (d, J = 6.0 Hz, 6H); 3.03 (t, J = 6.4 
Hz, 2H); 3.32 (s, 3H, OMe); 3.47 (s, 3H, OMe); 3.53 (s, 3H, OMe); 3.59 (s, 3H, OMe); 
4.35-4.65 (m, 4H, 2OCH); 4.74 (s, 2H); 5.01 (s, 2H); 6.46 (s, 1H); 6.55 (s, 1H); 6.61 
(br, 1H); 6.69-6.79 (m, 4H); 7.08-7.13 (m, 2H); 7.17-7.26 (m, 4H); 7.27-7.35 (m, 4H). 
13C NMR (CDCl3, 50.3 MHz) δ 21.8 (2q); 22.0 (2q); 28.9 (t); 42.8 (t); 50.7 (q); 54.9 (q); 
55.5 (q); 56.2 (q); 71.0 (t); 71.2 (d, t); 71.5 (d); 102.8 (d); 109.1 (d); 114.6 (2d); 115.8 
(d); 115.9 (d); 118.2 (s); 118.7 (s); 121.1 (s); 121.5 (s); 122.9 (d); 125.4 (s); 126.5 (2d); 
127.1 (2d); 127.5 (2d); 128.0 (2d); 128.2 (2d); 128.6 (s); 130.8 (s); 136.8 (s); 137.6 (s); 
 8
143.3 (s); 145.4 (s); 146.0 (s); 146.8 (s); 148.2 (s); 149.8 (s); 150.3 (s); 162.2 (s). MS 
(MALDI-TOF) 797 (M, 100), 798 (M+1, 54). 
Methyl 2-(2-benzyloxy-4-isopropoxy-5-methoxyphenyl)-1-(4-benzyloxy-3-
methoxyphenyl)-8-isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (15b)  
Following the general procedure A and starting from 14a (277 mg, 0.46 mmol) and 2-
(2-benzyloxy-4-isopropoxy-5-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(12a), a yellow oil (282 mg, 77%) was obtained. IR (film) ν 1692, 1254, 1212. 1H NMR 
(CDCl3, 200 MHz) δ 1.26 (d, J = 6.0 Hz, 6H); 1.36 (d, J = 6.0 Hz, 6H); 3.03 (t, J = 6.0 
Hz, 2H); 3.21 (s, 3H, OMe); 3.55 (s, 3H, OMe); 3.57 (s, 6H, 2OMe); 4.37 (h, J = 6.0 
Hz, 1H, OCH); 4.52 (h, J = 6.0 Hz, 1H, OCH); 4.63 (br, 2H); 4.82 (s, 2H); 5.12 (s, 2H); 
6.46 (s, 1H); 6.55 (s, 1H); 6.66 (s, 1H); 6.72 (br, 4H); 7.16-7.41 (m, 10H). 13C NMR 
(CDCl3, 50.3 MHz) δ 21.9 (2q); 22.0 (2q); 28.0 and 28.9 (t); 42.2 and 42.8 (t); 50.7 (q); 
55.0 (q); 55.5 (q); 56.2 (q); 70.5 (t); 71.1 (d); 71.3 (d); 71.5 (t); 104.5 (d); 109.0 (d); 
113.3 (d); 114.3 (d); 114.4 (d); 116.1 (d); 118.2 (s); 118.7 (s); 121.0 (s); 121.4 (s); 122.9 
(d); 125.4 (s); 126.5 (2d); 126.8 (2d); 127.1 (d); 127.5 (d); 127.7 (s); 128.0 (2d); 128.2 
(2d); 130.8 (s); 137.0 (s); 137.7 (s); 144.0 (s); 145.9 (s); 146.0 (s); 146.1 (s); 148.1 (s); 
148.8 (s); 150.2 (s); 162.2 (s). MS (ESI-TOF) 798 (M+1, 100), 799 (M+2, 39), 800 
(M+3, 7). HRMS m/z calcd. for C49H51NO9 798.3636, found 798.3621. 
Methyl 2-(2,4-dibenzyloxy-5-methoxyphenyl)-1-(4-benzyloxy-3-methoxyphenyl)-8-
isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (15c) 
Following the general procedure A and starting from 14a (255 mg, 0.42 mmol) and 2-
(2,4-dibenzyloxy-5-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12b), a 
reddish oil (246 mg, 69%) was obtained. IR (film) ν 1692, 1438, 1252, 1212. 1H NMR 
(CDCl3, 400 MHz) δ 1.38 (d, J = 6.0 Hz, 6H); 3.04 (t, J = 6.0 Hz, 2H); 3.24 (s, 3H, 
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OMe); 3.54 (s, 3H, OMe); 3.56 (s, 3H, OMe); 3.63 (s, 3H, OMe); 4.54 (h, J = 6.0 Hz, 
1H, OCH); 4.64 (br, 2H); 4.77 (s, 2H); 5.05 (s, 2H); 5.14 (s, 2H); 6.50 (s, 1H); 6.59 (s, 
1H); 6.67 (s, 1H); 6.71-6.77 (m, 4H); 7.11-7.14 (m, 2H); 7.21-7.42 (m, 13H). 13C NMR 
(CDCl3, 100 MHz) δ 22.0 (2q); 28.8 (t); 42.8 (t); 50.6 (q); 55.0 (q); 55.6 (q); 56.3 (q); 
70.5 (t); 71.0 (t); 71.2 (d); 71.5 (t); 102.9 (d); 109.1 (d); 113.5 (d); 114.46 (d); 114.54 
(d); 116.0 (d); 118.3 (s); 118.8 (s); 121.0 (s); 121.5 (s); 122.9 (d); 125.4 (s); 126.6 (2d); 
126.8 (2d); 127.19 (d); 127.21 (2d); 127.6 (2d); 127.9 (s); 128.0 (2d); 128.3 (2d); 128.3 
(2d); 128.6 (s); 130.8 (s); 136.9 (s); 137.1 (s); 137.7 (s); 143.4 (s); 146.1 (s); 146.3 (s); 
146.9 (s); 148.3 (s); 149.0 (s); 150.4 (s); 162.2 (s). MS (ESI-TOF) 846 (M+1, 100), 847 
(M+2, 49), 848 (M+3, 12). HRMS m/z calcd. for C53H52NO9 846.3636, found 846. 
3621. 
Methyl 2-(2,4-dibenzyloxy-5-methoxyphenyl)-8-isopropoxy-1-(4-isopropoxy-3-
methoxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (16a) 
Following the general procedure B and starting from 15a (686 mg, 0.86 mmol), a 
yellow oil (637 mg, 93%) was obtained. IR (film) ν 1682, 1380, 1121 cm-1. 1H NMR 
(CDCl3, 100 MHz) δ 1.32 (d, J = 6.0 Hz, 6H); 1.37 (d, J = 6.0 Hz, 6H); 3.42 (s, 6H, 
2OMe); 3.59 (s, 3H, OMe); 3.63 (s, 3H, OMe); 4.49 (h, J = 6.0 Hz, 1H, OCH); 4.64 (h, 
J = 6.0 Hz, 1H, OCH); 4.78 (br, 2H); 5.03 (s, 2H); 6.48 (s, 1H); 6.54-6.73 (m, 2H); 
6.79-6.94 (m, 3H); 7.03-7.11 (m, 3H); 7.15-7.20 (m, 3H); 7.23-7.34 (m, 6H); 9.31 (d, J 
= 7.6 Hz, 1H). 13C NMR (CDCl3, 50.3 MHz) δ 21.7 (2q); 22.0 (2q); 50.6 (q); 54.9 (q); 
55.5 (q); 56.3 (q); 70.9 (d); 71.1 (t); 71.2 (d); 71.3 (t); 102.5 (d); 105.4 (d); 110.3 (d); 
111.7 (d); 112.7 (s); 115.2 (d); 115.6 (d); 115.7 (s); 115.9 (d); 118.0 (s); 118.4 (s); 119.5 
(s); 123.2 (d); 123.6 (d); 126.4 (d); 127.1 (d); 127.2 (2d); 127.5 (2d); 128.0 (2d); 128.2 
(2d); 129.0 (s); 130.0 (s); 131.6 (s); 136.8 (s); 137.5 (s); 143.1 (s); 145.7 (s); 147.0 (s); 
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147.2 (s); 149.6 (s); 149.9 (s); 150.3 (s); 162.3 (s). MS (MALDI-TOF) 795 (M, 100), 
796 (M+1, 73).  
Methyl 2-(2-benzyloxy-4-isopropoxy-5-methoxyphenyl)-1-(4-benzyloxy-3-
methoxyphenyl)-8-isopropoxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate 
(16b) 
Following the general procedure B and starting from 15b (1.06 g, 1.32 mmol), a yellow 
oil (685 mg, 65%) was obtained. IR (film) ν 1704, 1377, 1214 cm-1. 1H NMR (CDCl3, 
400 MHz) δ 1.41 (2d, J = 6.0 Hz, 12H); 3.28 (s, 3H, OMe); 3.57 (br, 3H, OMe); 3.62 (s, 
3H, OMe); 3.65 (br, 3H, OMe ); 4.39 (h, J = 6.0 Hz, 1H, OCH); 4.65 (h, J = 6.0 Hz, 1H, 
OCH); 4.86 (br, 2H); 5.14-5.18 (m, 2H); 6.47 (br, 1H); 6.76-6.88 (m, 2H); 6.91 (d, J = 
7.6 Hz, 1H); 7.03 (s, 1H); 7.14-7.21 (m, 3H); 7.27-7.49 (m, 10H); 9.31 (d, J = 7.6 Hz, 
1H). 13C NMR (CDCl3, 100 MHz) δ 21.9 (2q); 22.0 (2q); 50.7 (q); 55.2 (q); 55.6 (q); 
56.4 (q); 70.6 (t); 70.8 (t); 71.0 (d); 71.5 (d); 104.3 (d); 105.5 (d); 110.3 (d); 111.8 (d); 
112.8 (s); 113.3 and 113.6 (d); 115.2 (d); 116.2 (d); 118.5 (s); 119.6 (s); 123.4 (d); 
123.7 (d); 127.0 (2d); 127.4 (s); 127.75 (2d); 128.2 (2d); 128.5 (2d); 128.6 (d); 128.7 
(s); 128.8 (d); 129.2 (s); 130.2 (s); 131.9 (s); 137.2 (s); 137.7 (s); 144.1 (s); 146.6 (s); 
147.4 (s); 149.7 (s); 150.4 (s); 162.6 (s). MS (ESI-TOF) 796 (M+1, 100), 797 (M+2, 
54). HRMS m/z calcd. for C49H50NO9 796.3480, found 796.3480.  
Methyl 2-(2,4-dibenzyloxy-5-methoxyphenyl)-1-(4-benzyloxy-3-methoxyphenyl)-8-
isopropoxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (16c) 
Following the general procedure B and starting from 15c (244 mg, 0.29 mmol), a 
yellow oil (181 mg, 74%) was obtained. IR (film) ν 1681, 1374, 1212 cm-1. 1H NMR 
(CDCl3, 100 MHz) δ 1.43 (d, J = 6.0 Hz, 6H); 3.30 (s, 3H, OMe); 3.52-3.65 (m, 9H, 3 
OMe); 4.60-4.90 (m, 3H); 5.07 (s, 2H); 5.18-5.21 (m, 2H); 6.50 (s, 1H); 6.59 (br, 1H); 
6.74 (br, 1H); 6.82-6.89 (m, 2H); 6.94 (d, J = 7.6 Hz, 1H); 7.06 (s, 1H); 7.09-7.15 (m, 
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2H); 7.20-7.23 (m, 4H); 7.30-7.46 (m, 10H); 9.33 (d, J = 7.6 Hz, 1H). 13C NMR 
(CDCl3, 50.3 MHz) δ 21.9 (2q); 50.7 (q); 55.1 (q); 55.7 (q); 56.4 (q); 70.6 (t); 70.9 (d); 
71.2 (t); 71.4 (t); 102.5 (d); 105.4 (d); 110.2 (d); 111.8 (d); 112.8 (s); 113.3 (d); 115.1 
(d); 116.0 (d); 118.1 (s); 118.4 (s); 119.5 (s); 123.3 (d); 123.6 (d); 126.5 (d); 126.9 (2d); 
127.2 (2d); 127.3 (2d); 127.7 (2d); 128.1 (2d); 128.3 (2d); 128.4 (2d); 129.0 (s); 130.1 
(s); 131.7 (s); 136.9 (s); 137.1 (s); 137.5 (s); 143.2 (s); 146.5 (s); 147.1 (s); 147.3 (s); 
149.0 (s); 149.6 (s); 150.4 (s); 162.4 (s). MS (MALDI-TOF) 844 (M+1, 100), 845 
(M+1, 52), 846 (M+3, 8). HRMS m/z calcd. for C53H50NO9 844.3480, found 844.3467. 
Methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-8-isopropoxy-1-(4-isopropoxy-3-
methoxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (17a) 
Following the general procedure C and starting from 16a (637 mg, 0.80 mmol), a brown 
oil (433 mg, 88%) was obtained. IR (film) ν 1685, 1381, 1223 cm-1. 1H NMR (CDCl3, 
100 MHz) δ 1.32 and 1.35 (d, J = 6.0 Hz, 6H); 1.42 (d, J = 6.0 Hz, 6H); 3.43 (s, 3H, 
OMe); 3.54 (br, 3H, OMe); 3.60 (br, 3H, OMe); 3.75 (s, 3H, OMe); 4.50 (h, J = 6.0 Hz, 
1H, OCH); 4.67 (h, J = 6.0 Hz, 1H, OCH); 6.33 and 6.45 (2br, 1H); 6.57 (s, 1H); 6.82-
7.00 (m, 3H); 7.05 (s, 1H); 7.17 and 7.34 (2br, 1H); 7.26 (s, 1H); 9.23 (d, J = 7.4 Hz, 
1H). 13C NMR (CDCl3, 50.3 MHz) δ 21.6 (2q); 21.8 (2q); 51.0 (q); 54.8 (q); 55.5 (q); 
56.2 (q); 70.8 (d); 71.1 (d); 102.5 (d); 105.3 (d); 110.1 (d); 112.1 (d); 112.4 (s); 112.8 
(s); 114.1 (s); 115.0 (d); 115.6 (d); 119.0 (s); 119.1 (d); 122.9 (s); 123.2 (d); 123.4 (d); 
128.4 (s); 130.2 (s); 130.6 (s); 139.8 (s); 145.5 (s); 145.7 (s); 147.3 (s); 148.2 (s); 149.5 
(s); 162.1 (s); 129.0 (s). MS (MALDI-TOF) 615 (M, 100), 616 (M+1, 27).  
Methyl 2-(2-hydroxy-4-isopropoxy-5-methoxyphenyl)-1-(4-hydroxy-3-
methoxyphenyl)-8-isopropoxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate 
(17b) 
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Following the general procedure C and starting from 16b (680 mg, 0.85 mmol), a 
brown oil (365 mg, 70%) was obtained. IR (film) ν 3440, 1684, 1381, 1218, 1121 cm-1. 
1H NMR (CDCl3, 200 MHz) δ 1.32 (d, J = 6.0 Hz, 6H); 1.38 (d, J = 6.0 Hz, 6H); 3.41 
(s, 3H, OMe); 3.48 and 3.55 (2s, 3H, OMe); 3.57 and 3.68 (2br, 3H, OMe); 3.72 (s, 3H, 
OMe); 4.50 (h, J = 6.0 Hz, 1H, OCH); 4.64 (h, J = 6.0 Hz, 1H, OCH); 5.82 (br, 1H, 
OH); 6.34 and 6.40 (2br, 1H); 6.52 (br, 1H); 6.73 (d, J = 7.2 Hz, 1H); 6.84-6.95 (m, 
2H); 7.00 (s, 1H); 7.06 and 7.15 (2d, J = 2.4 Hz, 1H); 7.26 (br, 1H); 9.13 (d, J = 7.2 Hz, 
1H). 13C NMR (CDCl3, 50.3 MHz) δ 21.8 (2q); 22.0 (2q); 51.3 (q); 55.2 (q); 55.8 (q); 
56.3 (q); 70.9 (d); 71.0 (d); 103.5 (d); 105.5 (d); 110.2 (d); 112.4 (d); 112.5 (s); 113.8 
(s); 113.9 (d); 115.2 and 115.4 (d); 119.3 (s); 123.1 (d); 123.4 (d); 124.4 (s); 124.5 (d); 
124.6 (s); 127.0 (s); 131.0 (s); 144.7 (s); 146.4 (s); 147.2 (s); 147.7 (s); 147.9 (s); 148.0 
(s); 149.8 (s); 162.3 (s). MS (MALDI-TOF) 615 (M, 100), 616 (M+1, 16).  
Methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-1-(4-hydroxy-3-methoxyphenyl)-8-
isopropoxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (17c) 
Following the general procedure C and starting from 16c (122 mg, 0.14 mmol), a 
yellow oil (80 mg, 95%) was obtained. IR (film) ν 3425, 1683, 1219, 1122 cm-1. 1H 
NMR (acetone-d6, 400 MHz) δ 1.33 (d, J = 6.0 Hz, 6H); 3.38 (s, 3H, OMe); 3.58 (s, 3H, 
OMe); 3.62 (s, 3H, OMe); 3.73 (br, 3H, OMe); 4.70 (h, J = 6.0 Hz, 1H, OCH); 5.60 (s, 
1H, OH); 6.37 (s, 1H); 6.57 (br, 1H); 6.82-6.88 (m, 2H); 7.07 (d, J = 7.5 Hz, 1H); 7.21 
(br, 1H); 7.26 (s, 1H); 7.56 (s, 1H); 9.26 (d, J = 7.5 Hz, 1H). 13C NMR (acetone-d6, 50.3 
MHz) δ 21.9 (2q); 51.3 (q); 55.3 (q); 55.9 (q); 56.4 (q); 71.0 (d); 102.5 (d); 105.5 (d); 
110.2 (d); 112.5 (d); 112.6 (s); 113.3 (s); 113.9 (d); 114.0 (d); 114.3 (d); 114.4 (s); 
119.3 (s); 123.2 (d); 123.5 (s); 124.4 (d); 127.2 (s); 130.1 (s); 131.1 (s); 140.0 (s); 144.6 
(s); 145.7 (s); 146.4 (s); 147.7 (s); 148.4 (s); 149.9 (s); 162.2 (s). MS (ESI-TOF) 574 
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(M+1, 100), 575 (M+2, 23). HRMS m/z calcd. for C32H32NO9 574.2072, found 
574.2055. 
4’,11-Diisopropyl-Lam-D (18a) 
Following the general procedure D and starting from 17a (433 mg, 0.70 mmol), a white 
solid (410 mg, quant.) was obtained. mp (MeCN) 218-220 ºC. IR (film) 
ν 3359, 1699, 1432, 1258, 1157 cm-1. 1H NMR (CDCl3, 200 MHz) δ 1.44 (d, J = 6.0 
Hz, 12H); 3.44 (s, 3H, OMe); 3.51 (s, 3H, OMe); 3.86 (s, 3H, OMe); 4.57-4.77 (m, 2H, 
2OCH); 6.72 (s, 1H); 6.98 (br, 1H); 7.02 (s, 1H); 7.09 (s, 1H); 7.15 (s, 1H); 7.16-7.18 
(m, 3H); 9.19 (d, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 50.3 MHz) δ 21.9 (4q); 55.1 (q); 
55.5 (q); 56.2 (q); 71.2 (d); 71.8 (d); 103.5 (d); 104.6 (d); 105.6 (d); 107.7 (s); 109.8 (s); 
110.3 (d); 110.8 (s); 112.2 (d); 115.0 (d); 116.9 (d); 118.9 (s); 123.1 (d); 123.9 (d); 
124.7 (s); 128.8 (s); 129.3 (s); 134.3 (s); 143.2 (s); 146.2 (s); 146.9 (s); 147.1 (s); 148.4 
(s); 150.0 (s); 151.3 (s); 155.4 (s). MS (MALDI-TOF) 583 (M, 100), 584 (M+1, 62). 
3,11-Diisopropyl-Lam-D (18b) 
Following the general procedure D and starting from 17b (365 mg, 0.59 mmol), a 
yellow solid (346 mg, quant. yield) was obtained. mp (MeCN) 130-132 ºC. IR (film) 
 3435, 1704, 1430, 1223 cm-1. 1H NMR (CDCl3, 200 MHz) δ 1.35 (d, J = 6.0 Hz, 6H); 
1.39 (d, J = 6.0 Hz, 6H); 3.42 (s, 3H, OMe); 3.44 (s, 3H, OMe); 3.85 (s, 3H, OMe); 4.49 
(h, J = 6.0 Hz, 1H); 4.65 (h, J = 6.0 Hz, 1H); 6.73 (s, 1H); 6.87 (s, 1H); 6.94 (d, J = 7.2 
Hz, 1H); 7.04 (s, 1H); 7.09 (s, 1H); 7.13-7.16 (m, 3H); 9.11 (d, J = 7.2 Hz, 1H). 13C 
NMR (CDCl3, 50.3 MHz) δ 21.7 (2q); 21.8 (2q); 55.1 (q); 55.4 (q); 56.1 (q); 71.0 (d); 
71.3 (d); 103.2 (d); 105.4 (d); 105.5 (d); 107.5 (s); 109.7 (s); 110.2 (d); 110.9 (s); 112.1 
(d); 113.9 (d); 115.2 (d); 118.8 (s); 122.8 (d); 124.5 (d); 127.1 (s); 129.2 (s); 134.3 (s); 
145.7 (s); 146.3 (s); 147.3 (s); 147.6 (s); 148.2 (s); 149.9 (s); 155.3 (s). MS (MALDI-
TOF) 583 (M, 100), 584 (M+1, 77).  
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11-Isopropyl-Lam-D (18c) 
Following the general procedure D and starting from 17c (80 mg, 0.14 mmol), a yellow 
solid (65 mg, 86%) was obtained. IR (film) ν 3312, 1710, 1432, 1264 cm-1. 1H NMR 
(acetone-d6, 400 MHz) δ 1.31 (d, J = 6.0 Hz, 6H); 3.35 (s, 3H, OMe); 3.39 (s, 3H, 
OMe); 3.77 (s, 3H, OMe); 4.75 (h, J = 6.0 Hz, 1H); 6.73 (s, 1H); 6.87 (s, 1H); 7.01 (dd, 
J = 8.0, 1.7 Hz, 1H); 7.10 (d, J = 8.0 Hz, 1H); 7.145 (s, 1H); 7.153 (d, J = 1.7 Hz, 1H); 
7.29 (d, J = 7.4 Hz, 1H); 7.44 (s, 1H); 9.05 (d, J = 7.4 Hz, 1H); 9.33 (s, 1H, OH); 9.83 
(s, 1H, OH). 13C NMR (acetone-d6, 100 MHz) δ 21.4 (2q); 54.1 (q); 54.8 (q); 55.7 (q); 
69.9 (d); 103.4 (d); 104.9 (s); 105.4 (d); 106.2 (d); 108.0 (s); 110.1 (d); 110.8 (d); 112.4 
(s); 114.7 (d); 116.1 (s); 118.0 (d); 121.8 (s); 123.5 (d); 124.1 (d); 125.0 (s); 128.7 (s); 
133.5 (s); 144.3 (s); 146.0 (s); 146.5 (s); 147.7 (s); 148.4 (s); 149.4 (s); 154.1 (s). MS 
(ESI-TOF) 542 (M+1, 100), 543 (M+2, 26). HRMS m/z calcd. for C31H28NO8 542.1809, 
found 542.1793. 
4’,11-Diisopropyl-3-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (19a) 
Following the general procedure E and starting from 18a (190 mg, 0.33 mmol), a 
yellow oil (204 mg, 84%) was obtained. IR (film) ν 1781, 1707, 1485, 1138 cm-1. 1H 
NMR (CDCl3, 400 MHz) δ 1.39 (d, J = 6.0 Hz, 12H); 3.35 (s, 3H, OMe); 3.39 (s, 3H, 
OMe); 3.40 (s, 3H, OMe); 3.52-3.54 (m, 2H); 3.62-3.65 (m, 2H); 3.68-3.71 (m, 2H); 
3.78-3.81 (m, 2H); 3.83 (s, OMe); 4.40 (s, 2H); 4.56-4.67 (m, 2H); 6.820 (s, 1H); 6.93 
(d, J = 7.2 Hz, 1H); 7.03 (s, 1H); 7.05 (s, 1H); 7.0-7.14 (m, 4H); 9.07 (d, J = 7.2 Hz, 
1H). 13C NMR (CDCl3, 100 MHz) δ 21.69 (q); 21.73 (q); 55.0 (q); 55.3 (q); 56.1 (q); 
58.8 (q); 68.1 (t); 70.4 (t); 70.5 (t); 70.8 (t); 71.0 (d); 71.65 (d); 71.72 (t); 105.4 (d); 
106.2 (d); 108.0 (s); 110.3 (d); 111.5 (s); 111.7 (d); 112.7 (d); 114.8 (d); 116.1 (s); 
116.8 (d); 118.8 (s); 122.7 (d); 123.6 (d); 124.5 (s); 128.0 (s); 128.2 (s); 134.2 (s); 138.8 
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(s); 145.3 (s); 147.1 (s); 147.1 (s); 148.4 (s); 150.1 (s); 151.3 (s); 154.7 (s); 168.2 (s). 
MS (MALDI-TOF) 743 (M, 100), 744 (M+1, 90), 745 (M+2, 29).  
3-[3-(2-(2-(2-(2-(2-(2-tert-
Butoxycarbonylaminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-
4’,11-diisopropyl-Lam-D (19b) 
Following the general procedure E and starting from 18a (154 mg, 0.26 mmol), a brown 
oil (205 mg, 76%) was obtained. IR (film) ν 3355, 1709, 1256, 1111 cm-1. 1H NMR 
(CDCl3, 400 MHz) δ 1.42 (d, J = 6.0 Hz, 6H); 1.43-1.45 (m, 15H, OiPr, tBuOC); 2.88 
(t, J = 6.5 Hz, 2H); 3.31 (br, 4H, 2CH2); 3.40 (s, 3H, OMe); 3.43 (s, 3H, OMe); 3.51-
3.54 (m, 4H, 2CH2); 3.61-3.66 (m, 16H); 3.75-3.80 (m, 2H, CH2); 3.88 (s, 3H, OMe); 
4.63 (h, J = 6.0 Hz, 1H); 4.70 (h, J = 6.0 Hz, 1H); 5.16 (br, 1H); 6.86 (s, 1H); 7.06 (d, J 
= 7.6 Hz, 1H); 7.10 (s, 1H); 7.12 (s, 1H); 7.15-7.19 (m, 4H); 9.23 (d, J = 7.6 Hz, 1H). 
13C NMR (CDCl3, 100 MHz) δ 21.66 (q); 21.69 (q); 28.2 (q); 34.5 (t); 40.1 (t); 54.9 (q); 
55.3 (q); 56.0 (q); 66.2 (t); 69.9 (2t); 70.0 (2t); 70.2 (2t); 70.3 (7t); 71.0 (d); 71.6 (d); 
105.4 (d); 106.2 (d); 110.3 (d); 111.4 (s); 111.5 (s); 111.8 (d); 111.9 (s); 112.7 (d); 
114.7 (d); 115.9 (s); 116.8 (d); 118.8 (s); 122.7 (s); 122.8 (d); 123.6 (d); 124.5 (s); 128.2 
(s); 139.3 (s); 147.1 (s); 147.2 (s); 148.4 (s); 150.1 (s); 151.3 (s); 154.8 (s); 156.0 (s); 
169.2 (s); 174.7 (s). MS (MALDI-TOF) 919 ([M-Boc], 100), 920 ([M-Boc]+1, 55).  
3,11-Diisopropyl-4’-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (19c) 
Following the general procedure E and starting from 18b (104 mg, 0.18 mmol), a 
yellow oil (127 mg, 96%) was obtained. IR (film) ν 1781, 1704, 1113 cm-1. 1H NMR 
(CDCl3, 400 MHz) δ 1.31 (d, J = 6.0 Hz, 6H); 1.35 (d, J = 6.0 Hz, 6H); 3.32 (s, 3H, 
OMe); 3.40 (2s, 6H, 2OMe); 3.45-3.52 (m, 2H); 3.55-3.63 (m, 2H); 3.65-3.71 (m, 2H); 
3.74 (s, 3H, OMe); 3.78-3.82 (m, 2H); 4.40-4.49 (m, 3H, OCH, CH2); 4.61 (h, J = 6.0 
Hz, 1H); 6.62 (s, 1H); 6.85 (s, 1H); 6.93 (d, J = 7.2 Hz, 1H); 7.00-7.03 (m, 2H); 7.16-
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7.19 (m, 2H); 7.22 (d, J = 8.0 Hz, 1H); 9.11 (d, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 100 
MHz) δ 21.67 (q); 21.73 (q); 55.4 (q); 55.6 (q); 56.1 (q); 58.9 (q); 68.5 (t); 70.4 (t); 70.5 
(t); 70.9 (t); 71.1 (d); 71.3 (d); 71.8 (t); 103.3 (d); 105.1 (d); 105.3 (d); 107.7 (s); 109.5 
(s); 110.1 (s); 110.4 (d); 112.3 (d); 115.4 (d); 118.6 (s); 122.8 (d); 123.5 (d); 123.9 (d); 
124.5 (s); 129.1 (s); 134.1 (s); 135.0 (s); 139.3 (s); 146.3 (s); 146.6 (s); 147.8 (s); 148.4 
(s); 150.3 (s); 151.8 (s); 155.3 (s); 168.2 (s); 170.7 (s). MS (MALDI-TOF) 743 (M, 75), 
744 (M+1, 100), 745 (M+2, 45).  
4’-[3-(2-(2-(2-(2-(2-(2-tert-
Butoxycarbonylaminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]- 
3,11-diisopropyl-Lam-D (19d) 
Following the general procedure E and starting from 18b (82 mg, 0.14 mmol), a brown 
oil (143 mg, quant. yield) was obtained. IR (film) ν 3362, 1764, 1707, 1268, 1113 cm-1. 
1H NMR (CDCl3, 400 MHz) δ 1.41 (d, J = 6.0 Hz, 6H); 1.42-1.44 (m, 15H, OiPr, 
tBuOC); 2.94 (t, J = 6.5 Hz, 2H); 3.29-3.32 (m, 4H, 2CH2); 3.48 (s, 6H, 2OMe); 3.61-
3.71 (m, 20H, 10CH2); 3.81 (s, 3H, OMe); 3.94 (t, J = 6.6 Hz, 2H, CH2); 4.58 (h, J = 
6.0 Hz, 1H); 4.70 (h, J = 6.2 Hz, 1H); 5.09 (br, 1H); 6.72 (s, 1H); 6.98 (s, 1H); 7.05 (d, 
J = 7.4 Hz, 1H); 7.11 (s, 1H); 7.13 (s, 1H); 7.21 (d, J = 1.6 Hz, 1H); 7.24 (dd, J = 8.0, 
1.6 Hz, 1H); 7.30 (d, J = 8.0 Hz, 1H); 9.24 (d, J = 7.4 Hz, 1H). 13C NMR (CDCl3, 100 
MHz) δ 21.6 (2q); 21.7 (2q); 28.3 (q); 34.6 (t); 40.2 (t); 55.4 (q); 55.5 (q); 56.1 (q); 66.3 
(t); 70.0 (t); 70.1 (t); 70.2 (t); 70.3 (t); 70.4 (5t); 71.0 (t); 71.3 (t); 103.3 (d); 105.1 (d); 
105.3 (d); 107.7 (s); 109.5 (s); 110.2 (s); 110.3 (d); 112.3 (d); 115.3 (d); 118.6 (s); 122.8 
(d); 123.7 (d); 123.8 (d); 124.4 (s); 129.1 (s); 134.1 (s); 134.7 (s); 139.8 (s); 146.3 (s); 
146.5 (s); 147.7 (s); 148.4 (s); 150.3 (s); 152.0 (s); 155.3 (s); 155.9 (s); 169.2 (s). MS 
(MALDI-TOF) 919 ([M-Boc], 100), 1018 (M, 35). 
11-Isopropyl-3,4’-bis(2-(2-methoxyethoxy)acetyl)-Lam-D (19e)  
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Following the general procedure E and starting from 18c (32 mg, 0.06 mmol), a yellow 
solid (32 mg, 71%) was obtained. mp (MeCN) 173-175 ºC. IR (film) 
ν 1781, 1707, 1274, 1116 cm-1. 1H NMR (CDCl3, 200 MHz) δ 1.44 (d, J = 6.0 Hz, 6H); 
3.41 (s, 3H, OMe); 3.45 (s, 3H, OMe); 3.46 (s, 3H, OMe); 3.49 (s, 3H, OMe); 3.61-3.70 
(m, 4H, 2CH2); 3.76-3.90 (m, 7H, OMe, 2CH2); 4.45 (s, 2H); 4.53 (s, 2H); 4.71 (h, J = 
6.0 Hz, 1H); 6.81 (s, 1H); 7.04 (d, J = 7.4 Hz, 1H); 7.11 (s, 1H); 7.12 (s, 1H); 7.14 (s, 
1H); 7.23-7.28 (m, 2H); 7.33 (d, J = 8.0 Hz, 1H); 9.19 (d, J = 7.4 Hz, 1H). 13C NMR 
(CDCl3, 50.3 MHz) δ 21.9 (2q); 55.6 (q); 55.8 (q); 56.2 (q); 59.0 (2q); 68.3 (t); 68.4 (t); 
70.8 (t); 70.9 (t); 71.2 (d); 71.9 (2t); 105.3 (d); 106.1 (d); 108.3 (s); 110.3 (d); 110.8 (s); 
111.9 (d); 112.9 (d); 115.3 (d); 115.9 (s); 118.7 (s); 122.8 (d); 123.7 (d); 123.8 (d); 
124.5 (s); 128.1 (s); 134.1 (s); 134.8 (s); 138.9 (s); 139.5 (s); 145.3 (s); 147.4 (s); 148.6 
(s); 150.4 (s); 152.0 (s); 154.8 (s); 168.2 (s). MS (ESI-TOF) 774 (M+1, 100), 775 (M+2, 
31), 776 (M+3, 7). HRMS m/z calcd. for C41H44NO14 774.2756, found 774.2744.  
11-Isopropyl-3,4’-bis(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (19f) 
Following the general procedure E and starting from 18c (32 mg, 0.06 mmol), a yellow 
solid (50 mg, 97%) was obtained. mp (MeCN) 125-127 ºC. IR (film) 
ν 1708, 1464, 1275, 1114 cm-1. 1H NMR (CDCl3, 400 MHz) δ 1.44 (d, J = 6.0 Hz, 6H); 
3.39 (s, 3H, OMe); 3.42 (s, 3H, OMe); 3.46 (s, 3H, OMe); 3.49 (s, 3H, OMe); 3.54-3.63 
(m, 4H, 2CH2); 3.65-3.92 (m, 15H, OMe, 6CH2); 4.46 (s, 2H); 4.53 (s, 2H); 4.71 (h, J = 
6.0 Hz, 1H); 6.82 (s, 1H); 7.06 (d, J = 7.4 Hz, 1H); 7.12 (s, 2H); 7.16 (s, 1H); 7.23-7.35 
(m, 3H); 9.21 (d, J = 7.4 Hz, 1H). 13C NMR (CDCl3, 50.3 MHz) δ 21.9 (2q); 55.6 (q); 
55.8 (q); 56.2 (q); 59.0 (2q); 68.3 (t); 68.4 (t); 70.5 (2t); 70.6 (t); 70.7 (t); 71.0 (2t); 71.2 
(d); 71.9 (2t); 105.3 (d); 106.1 (d); 108.3 (s); 110.4 (d); 110.8 (s); 112.0 (d); 113.0 (d); 
115.3 (d); 115.9 (s); 118.7 (s); 122.8 (d); 123.7 (2d); 124.5 (s); 124.6 (s); 128.1 (s); 
134.2 (s); 134.8 (s); 139.0 (s); 139.5 (s); 145.4 (s); 147.4 (s); 148.6 (s); 150.5 (s); 152.0 
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(s); 154.9 (s); 168.2 (s). MS (ESI-TOF) 862 (M+1, 83), 863 (M+2, 20). HRMS m/z 
calcd. for C45H52NO16 862.3281, found 862.3266. 
3,4’,11-tris(2-(2-methoxyethoxy)acetyl)-Lam-D (8) 
Following the general procedure E and starting from Lam-D (15) (38 mg, 0.08 mmol), 
elution with hexane/THF (60:40 to 40:60) gave a white solid (26 mg, 40%). mp 
(MeCN) 148-149 ºC. IR (film) ν 1779, 1707, 1117 cm-1. 1H NMR (CDCl3, 400 MHz) δ 
3.405 (s, 3H, OMe); 3.410 (s, 3H, OMe); 3.44 (s, 3H, OMe); 3.45 (s, 3H, OMe); 3.46 (s, 
3H, OMe); 3.61-3.64 (m, 4H, 2CH2); 3.66-3.68 (m, 2H, CH2); 3.80-3.88 (m, 9H, OMe, 
3CH2); 4.45 (s, 2H); 4.48 (s, 2H); 4.52 (s, 2H); 6.80 (s, 1H); 7.05 (d, J = 7.6 Hz, 1H); 
7.16 (s, 1H); 7.21 (s, 1H); 7.24 (d, J = 1.6 Hz, 1H); 7.25-7.28 (m, 1H); 7.33 (d, J = 8.0 
Hz, 1H); 7.42 (s, 1H); 9.22 (d, J = 7.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 55.7 (q); 
55.8 (q); 56.3 (q); 58.99 (q); 59.02 (q); 59.03 (q) 68.32 (t); 68.34 (t); 68.4 (t); 70.9 (2t); 
71.0 (t); 71.9 (2t); 72.0 (t); 106.1 (d); 106.4 (d); 109.1 (s); 112.1 (d); 112.3 (s); 112.8 
(d); 115.1 (d); 115.8 (s); 120.7 (d); 123.2 (s); 123.6 (s); 123.8 (2d); 124.0 (d); 128.1 (s); 
133.4 (s); 134.5 (s); 139.2 (s); 139.7 (s); 140.4 (s); 145.4 (s); 147.6 (s); 150.8 (s); 152.3 
(s); 154.9 (s); 168.3 (s); 168.4 (s). MS (ESI-TOF) 848 (M+1, 100), 849 (M+2, 35). 
HRMS m/z calcd. for C43H46NO17 848.2760, found 848.2751. 
3,4’,11-tris(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (9) 
Following the general procedure E and starting from Lam-D (15) (37 mg, 0.08 mmol), 
elution with hexane/THF (60:40 to 40:60) gave a pink solid (34 mg, 46%). mp (MeCN) 
137-139 ºC. IR (film) ν 1779, 1707, 1117 cm-1. 1H NMR (CDCl3, 400 MHz) δ 3.39 (s, 
6H, 2OMe); 3.41 (s, 3H, OMe); 3.447 (s, 3H, OMe); 3.451 (s, 3H, OMe); 3.54-3.61 (m, 
6H, 3CH2); 3.66-3.79 (m, 12H, 6CH2); 3.82-3.89 (m, 9H, OMe, 3CH2); 4.45 (s, 2H); 
4.48 (s, 2H); 4.52 (s, 2H); 6.80 (s, 1H); 7.04 (d, J = 7.6 Hz, 1H); 7.15 (s, 1H); 7.21 (s, 
1H); 7.24-7.27 (m, 2H); 7.32 (d, J = 8.0 Hz, 1H); 7.42 (s, 1H); 9.21 (d, J = 7.6 Hz, 1H). 
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13C NMR (CDCl3, 100 MHz) δ 55.7 (q); 55.8 (q); 56.3 (q); 59.0 (3q); 68.29 (t); 68.33 
(t); 68.4 (t); 70.53 (2t); 70.60 (t); 70.62 (2t); 70.67 (t); 71.00 (t); 71.01 (t); 71.04 (t); 
71.88 (2t); 71.90 (t); 106.1 (d); 106.4 (d); 109.1 (s); 112.1 (d); 112.3 (s); 112.8 (d); 
115.1 (d); 115.8 (s); 120.6 (d); 123.1 (s); 123.6 (d); 123.7 (s); 123.8 (d); 124.0 (d); 
128.1 (s); 133.4 (s); 134.5 (s); 139.2 (s); 139.7 (s); 140.4 (s); 145.4 (s); 147.6 (s); 150.8 
(s); 152.3 (s); 154.9 (s); 168.3 (s); 168.5 (s). MS (ESI-TOF) 980 (M+1, 100), 981 (M+2, 
62). HRMS m/z calcd. for C49H58NO20 980.3547, found 980.3529. 
3-(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (2) 
Following the general procedure F and starting from 19a (187 mg, 0.26 mmol), elution 
with hexane/THF (60:40 to 40:60) gave a yellow solid (73 mg, 44%). mp (MeCN) 163-
164 ºC. IR (film) ν 3284, 1786, 1684, 1424 cm-1. 1H NMR (CDCl3, 400 MHz) δ 3.38 (s, 
3H, OMe); 3.42 (s, 3H, OMe); 3.50 (s, 3H, OMe); 3.54-3.58 (m, 2H); 3.64-3.69 (m, 
2H); 3.70-3.75 (m, 2H); 3.80-3.84 (m, 2H); 3.91 (s, OMe); 4.43 (s, 2H); 6.04 (br, 1H, 
OH); 6.28 (br, 1H, OH); 6.82 (s, 1H); 6.88 (d, J = 7.2 Hz, 1H); 7.04 (s, 1H); 7.09 (s, 
1H); 7.10-7.11 (m, 1H); 7.13 (s, 2H); 7.18 (d, J = 7.6 Hz, 1H); 9.02 (d, J = 7.2 Hz, 1H). 
13C NMR (CDCl3, 100 MHz) δ 55.3 (q); 55.5 (q); 56.3 (q); 59.0 (q); 68.2 (t); 70.4 (t); 
70.6 (t); 70.9 (t); 71.8 (t); 104.9 (d); 106.3 (d); 108.0 (s); 110.9 (d); 111.5 (s); 111.7 (d); 
112.7 (d); 113.8 (d); 115.3 (d); 116.1 (s); 118.6 (s); 122.8 (d); 124.5 (d); 125.1 (s); 
127.0 (s); 128.1 (s); 134.5 (s); 138.8 (s); 145.3 (s); 145.8 (s); 146.9 (s); 147.1 (s); 147.2 
(s); 147.5 (s); 154.8 (s); 168.4 (s). MS (ESI-TOF) 660 (M+1, 100), 682 (M+Na, 80). 
HRMS m/z calcd. for C35H34NO12 660.2075, found 660.2062. 
3-[3-(2-(2-(2-(2-(2-(2-
Aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-Lam-D (3) 
Following the general procedure F and starting from 19b (140 mg, 0.14 mmol), elution 
with CH2Cl2/MeOH (95:5 to 90:10) gave a yellow oil (68 mg, 59%). IR (film) 
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ν 3127, 1702, 1420, 1278 cm-1. 1H NMR (CDCl3, 400 MHz) δ 2.60 and 2.86 (2t, J = 6.4 
Hz, 2H); 3.20 (br, 2H); 3.43 (s, 3H, OMe); 3.50 (s, 3H, OMe); 3.63-3.70 (m, 20H); 
3.83-3.89 (m, 4H); 3.90 (s, 3H, OMe) 6.82 (s, 1H); 6.93 (d, J = 7.5 Hz, 1H); 7.01 (s, 
1H); 7.10 (dd, J = 8.0, 1.6 Hz, 1H); 7.12 (2s, 2H); 7.22 (s, 1H); 7.24 (d, J = 8.0 Hz, 1H); 
7.92 (br, 4H, NH2, 2 OH); 9.10 (d, J = 7.5 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 34.6 
(t); 40.2 (t); 55.2 (q); 55.5 (q); 56.2 (q); 66.2 (t); 66.6 (t); 69.7 (t); 69.8 (t); 69.9 (t); 70.0 
(2t); 70.1 (t); 70.2 (2t); 70.3 (t); 70.4 (t); 104.9 (d); 106.3 (d); 107.8 (s); 111.0 (d); 111.5 
(s); 111.7 (d); 112.7 (d); 113.9 (d); 115.6 (d); 115.9 (s); 118.5 (s); 122.7 (d); 124.3 (d); 
125.1 (s); 126.7 (s); 128.1 (s); 134.5 (s); 139.2 (s); 145.2 (s); 146.0 (s); 147.2 (s); 147.3 
(s); 147.4 (s); 147.7 (s); 154.8 (s); 169.5 (s). MS (ESI-TOF) 835 (M+1, 100); 836 (M+2, 
40), 837 (M+3, 8). HRMS m/z calcd. for C43H51N2O15 835.3283, found 835.3277. 
4’-(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (4) 
Following the general procedure F and starting from 19c (111 mg, 0.15 mmol), elution 
with hexane/THF (60:40 to 40:60) gave a yellow solid (55 mg, 55%). mp (MeCN) 201-
203 ºC. IR (film) ν 3455, 1679, 1426 cm-1. 1H NMR (CDCl3, 400 MHz) δ 3.41 (s, 3H, 
OMe); 3.54 (s, 3H, OMe); 3.55 (s, 3H, OMe); 3.58-3.62 (m, 2H); 3.68-3.75 (m, 2H); 
3.76-3.81 (m, 2H); 3.83 (s, OMe); 3.86-3.91 (m, 2H); 4.53 (s, 2H); 5.88 (br, 1H, OH); 
5.98 (br, 1H, OH); 6.66 (s, 1H); 6.93-7.10 (m, 2H); 7.07 (s, 1H); 7.18 (s, 1H); 7.23-7.28 
(m, 2H); 7.32 (d, J = 8.0 Hz, 1H); 9.17 (d, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 100 MHz) 
δ 55.8 (q); 55.9 (q); 56.3 (q); 59.1 (q); 68.5 (t); 70.6 (t); 70.7 (t); 71.1 (t); 71.9 (t); 103.6 
(d); 104.4 (d); 104.7 (d); 109.6 (s); 110.0 (s); 110.8 (d); 115.5 (d); 118.6 (s); 123.3 (s); 
123.7 (d); 124.0 (d); 125.5 (d); 125.6 (d); 128.2 (s); 129.3 (s); 134.3 (s); 135.4 (s); 135.8 
(s); 139.5 (s); 143.5 (s); 146.4 (s); 146.9 (s); 147.0 (s); 147.2 (s); 152.1 (s); 168.5 (s). 
MS (ESI-TOF) 660 (M+1, 100), 682 (M+Na, 33). HRMS m/z calcd. for C35H34NO12 
660.2075, found 660.2065. 
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4’-[3-(2-(2-(2-(2-(2-(2-
Aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-Lam-D (5)  
Following the general procedure F and starting from 19d (130 mg, 0.13 mmol), elution 
with CH2Cl2/MeOH (95:15 to 85:15) gave a brown oil (61 mg, 57%). IR (film) 
ν 3133, 1700, 1425, 1277 cm-1. 1H NMR (CDCl3, 400 MHz) δ 2.60 and 2.95 (2t, J = 6.4 
Hz, 2H); 3.16-3.24 (m, 2H); 3.43 and 3.47 (s, 3H, OMe); 3.52 (s, 3H, OMe); 3.62-3.77 
(m, 20H); 3.83 (s, 3H, OMe); 3.89-3.96 (m, 4H); 6.65 (s, 1H); 6.95 (d, J = 7.4 Hz, 1H); 
6.99 (s, 1H); 7.06 (s, 1H); 7.19-7.24 (m, 2H); 7.25 (d, J = 1.6 Hz, 1H); 7.26-7.31 (m, 
1H); 9.10 (d, J = 7.4 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 34.7 (t); 40.2 (t); 55.6 (q); 
55.8 (q); 56.3 (q); 66.4 (t); 66.7 (t); 69.7 (t); 69.8 (t); 69.9 (2t); 70.0 (2t); 70.1 (t); 70.2 
(t); 70.3 (t); 70.4 (t); 103.7 (d); 104.6 (d); 104.8 (d); 107.7 (s); 109.4 and 109.9 (s); 
111.0 (d); 112.3 (d); 115.5 (d); 118.4 (s); 123.0 (d); 123.9 (2d); 125.2 (s); 129.2 (s); 
134.3 (s); 135.0 (s); 139.9 (s); 143.8 (s); 146.6 (s); 146.8 (s); 147.2 (s); 147.5 (s); 152.1 
(s); 155.4 (s); 169.5 (s); 172.1 (s). MS (ESI-TOF) 835 (M+1, 100); 836 (M+2, 44), 837 
(M+3, 23). HRMS m/z calcd. for C43H51N2O15 835.3283, found 835.3277. 
3,4’-bis(2-(2-Methoxyethoxy)acetyl)-Lam-D (6) 
Following the general procedure F and starting from 19e (41 mg, 0.05 mmol), elution 
with hexane/THF (60:40 to 40:60) gave a yellow solid (19 mg, 48%). mp (MeCN) 162-
164 ºC. IR (film) ν 3170, 1780, 1681, 1425 cm-1. 1H NMR (CDCl3, 400 MHz) δ 3.40 (s, 
3H, OMe); 3.44 (s, 3H, OMe); 3.45 (s, 3H, OMe); 3.56 (s, 3H, OMe); 3.61-3.64 (m, 
2H); 3.66-3.68 (m, 2H); 3.80-3.82 (m, 2H); 3.83 (s, 3H, OMe); 3.85-3.88 (m, 2H); 4.45 
(s, 2H); 4.52 (s, 2H); 6.00 (br, 1H, OH); 6.82 (s, 1H); 6.95-6.99 (m, 1H); 7.02 (d, J = 
7.2 Hz, 1H); 7.06 (s, 1H); 7.14 (s, 1H); 7.18 (s, 1H); 7.24 (d, J = 2.0 Hz, 1H); 7.32 (d, J 
= 8.0 Hz, 1H); 9.17 (d, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 55.76 (q); 55.80 
(q); 56.3 (q); 58.99 (q); 59.04 (q); 68.3 (t); 68.4 (t); 70.9 (t); 71.0 (t); 71.9 (t); 72.0 (t); 
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104.7 (d); 106.2 (d); 108.4 (s); 110.7 (s); 110.9 (d); 112.0 (d); 113.0 (d); 115.3 (d); 
116.0 (s); 118.6 (s); 123.1 (d); 123.8 (d); 125.2 (s); 125.5 (d); 128.1 (s); 134.4 (s); 134.9 
(s); 139.1 (s); 139.6 (s); 145.5 (s); 147.0 (s); 147.3 (s); 147.5 (s); 152.2 (s); 154.9 (s); 
168.3 (s); 168.4 (s). MS (ESI-TOF) 732 (M+1, 100), 733 (M+2, 32); 734 (M+3, 9). 
HRMS m/z calcd. for C38H38NO14 732.2287, found 732.2307. 
3,4’-bis(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (7)  
Following the general procedure F and starting from 19f (48 mg, 0.06 mmol), elution 
with hexane/THF (60:40 to 40:60) gave a white solid (8 mg, 19%). mp (MeCN) 151-
152 ºC. IR (film) ν 3204, 1780, 1681, 1425 cm-1. 1H NMR (CDCl3, 400 MHz) δ 3.39 (s, 
3H, OMe); 3.41 (s, 3H, OMe); 3.44 (s, 3H, OMe); 3.55-3.58 (m, 5H, OMe, CH2); 3.59-
3.62 (m, 4H, 2CH2); 3.66-3.75 (m, 6H, 3CH2); 3.77-3.79 (m, 2H, CH2); 3.83 (br, 3H, 
OMe); 3.87-3.90 (m, 2H, CH2); 4.45 (s, 2H); 4.53 (s, 2H); 5.97 (br, 1H); 6.82 (s, 1H); 
6.97-7.08 (m, 2H); 7.15 (s, 1H); 7.20 (s, 1H); 7.23-7.25 (m, 2H); 7.32 (d, J = 8.0 Hz, 
1H); 9.20 (d, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 55.76 (q); 55.82 (q); 56.3 
(q); 59.1 (2q); 68.3 (t); 68.5 (t); 70.55 (t); 70.62 (t); 70.65 (t); 70.70 (t); 71.0 (t); 71.1 (t); 
71.90 (t); 71.93 (t); 103.6 (s); 104.4 (s); 104.7 (d); 106.2 (d); 110.8 (s); 110.9 (d); 112.1 
(d); 112.4 (s); 113.0 (d); 115.3 (d); 115.5 (s); 116.0 (s); 118.6 (s); 123.1 (s); 123.8 (d); 
123.9 (d); 125.3 (s); 125.5 (d); 135.0 (s); 139.6 (s); 145.5 (s); 147.0 (s); 147.5 (s); 152.2 
(s); 155.0 (s); 168.4 (s); 168.5 (s). MS (ESI-TOF) 820 (M+1, 100), 821 (M+2, 39); 822 
(M+2, 14). HRMS m/z calcd. for C42H46NO16 820.2811, found 820.2797. 
Cell Lines and Culture. Established human-derived cell lines used in this study were 
purchased from ATCC (American Type Culture Collection): A-549, human lung 
carcinoma, BJ, Skin Fibroblast, HT-29, human colorectal adenocarcinoma, and MDA-
MB 231, human breast adenocarcinoma. All cell lines were maintained in DMEM 
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supplemented with 10% FBS and 100 units/mL penicillin and streptomycin at 37 °C and 
5% CO2. 
GI50 Analysis. Triplicate cultures were incubated for 72 h in the presence or absence 
of test compounds 1-9 (at ten concentrations, typically ranging from 0.0026 to 10 
µg/mL). 
A colorimetric assay using SRB was adapted for a quant. measurement of cell growth 
and viability, following a previously described method (16). Cells were plated in 96-
well microtiter plates at a density of 5 × 103/well and incubated for 24 h. One plate from 
each different cell line was fixed, stained and used for Tz reference (see next 
paragraph). The cells were then treated with vehicle alone (control) or the test 
compounds at the concentrations indicated. The treated cells were incubated for 
additional 72 h, and then assayed for cytotoxicity via colorimetric analysis. 
The cells were washed twice with PBS, fixed for 15 min in 1% glutaraldehyde 
solution, rinsed twice in PBS, and stained in 0.4% SRB solution for 30 min at room 
temperature. The cells were then rinsed several times in 1% acetic acid solution and air-
dried. SRB was then extracted in 10 mM trizma base solution, and the absorbance at 
490 nm was then measured. Cell survival is expressed as percentage of control cell 
growth. 
Dose−response curves were obtained by using the NCI algorithm (17): Tz = number 
of control cells at time t0, C = number of control cells at time t, and T = number of 
treated cells at time t. 
If Tz < T < C (growth inhibition), then the result is 100 × ([T − Tz]/[C − Tz]). 
If T < Tz (net cell death), then the result is 100 × ([T − Tz]/Tz). 
After dose-curve generation, the results were expressed as GI50. 
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General Treatments for Imaging. A-549, MDA-MB-231 and HT-29 cells were 
seeded onto MatTek (Ashland, USA) glass bottom microwell dishes at 30 103 cells/cm2. 
After 24 h, the culture medium was discarded, and then replaced by fresh DMEM 
medium containing compound 9 at 25 nM. A negative control (no compound) was also 
used. The cells were then incubated for 48 h at 37 ºC.  
The following dyes were used for co-localization experiments: WGA-FITC (Sigma, 
USA), and Mitotracker Red (Molecular Probes). Standard staining protocols were 
employed for live-cell imaging. Images were then subsequently acquired within the 
following 30 min. 
Confocal Laser Scanning Microscopy. Confocal laser scanning microscopy was 
performed with a Leica TCS SPII spectral confocal laser scanning microscope (Leica 
Microsystems Heidelberg GmbH, Mannheim, Germany), using a 63× objective. FITC 
fluorescence was excited with an Ar laser at 488 nm. Lam-D and its derivatives were 
excited at 351 nm. Mitotracker was excited at 543 nm. The same microscope settings 
were maintained for each conjugate and concentration. To avoid crosstalk, two-
fluorescence scanning was performed in a sequential mode.  
Apoptosis Assay. The methodology used is based on fluorochrome inhibitors of 
caspases (FLICA; CaspaTag in situ caspase detection kits, Chemicon International, U.S. 
and Canada). The inhibitors are cell permeable and non-cytotoxic. Once inside the cell, 
the inhibitor covalently binds to the active caspase. This kit uses a carboxyfluorescein-
labeled fluoromethyl ketone peptide inhibitor of caspase-3 (FAM-DEVD-FMK), which 
fluoresces green. When added to a group of cells, the FAM-DEVD-FMK probe enters 
each cell and covalently binds to a reactive cysteine residue in the large subunit of the 
active caspase heterodimer, thereby inhibiting further enzymatic activity (18). 
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Cell cultures previously incubated with Lam-D for 48 h at a concentration of 25 nM 
were tested for apoptosis determination. After the latter drug treatments, 30 × FLICA 
reagent was added at 1:15 dilution in culture medium, and then incubated for 1 h at 37 
°C. The cells were then washed with PBS, and subsequently analyzed by confocal 
scanning microscopy. The green fluorescence signal was a direct measure of the amount 
of active caspase-3/7 present in the cell at the time the reagent was added. 
Uptake Measurements by FACS Flow Cytometry. 1 106 A-549, BJ, MDA-MB-231 
and HT-29 cells were seeded onto 25 cm2 cell culture flasks (Nalgene Nunc 
International, Naperville, USA) with 10 mL of DMEM. After 12 h, the culture medium 
was discarded and replaced by fresh DMEM medium containing compounds 1-9 at a 
concentration of 1µM. A negative control (no compound) was also used. Cells were 
then incubated for 12 h at 37 ºC. After incubation, cells were washed 3 × PBS, detached 
with trypsin-EDTA 0.25% and centrifuged at 1000 × rpm. Finally, the medium was 
decanted, and the cellular pellet was resuspended in PBS and kept at 0 ºC until 
measurements were performed. Fluorescence analysis was performed with a MoFlo 
cytometer (DakoCytomation, Colorado, USA), using the 351 nm excitation line of Ar 
laser (25 mW) and emission detection at 450 nm (tolerance range ± 65 nm). CIQ is 
expressed as a percentage value in reference to Lam-D. It was calculated as a division of 
the fluorescence value obtained by the Lam-D fluorescence control under the same 
experimental conditions. 
Cell Cycle Analysis. Cell cycle analysis were performed by DRAQ5 (Biostatus) 
staining to determine DNA content. DRAQ5 was added to the previous PBS cell culture 
suspensions (1 µL / 4 105 cells), incubated for 15 min at 37 ºC, and the cells were 
directly analyzed without any further treatment. Fluorescence analysis was performed 
with a MoFlo cytometer (DakoCytomation, Colorado, USA), using the 488 nm 
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excitation line of an Ar laser (150 mW) and emission detection at 670 nm (tolerance 
range ± 30 nm). Cell cycle profile was analyzed using Cell Quest software. 
RESULTS 
Lam-D contains three phenolic sites susceptible to modification. Despite previous 
SAR studies that highlighted the relevance of the phenolic residues at the C-3 and C-11 
positions of Lam-D (3, 19), and their essential role for cytotoxicity and topoisomerase I 
inhibition (3), in this study, the free OH groups were chosen for attachment the PEG 
moiety. As esters readily hydrolyze under physiological conditions, our group 
envisioned that these derivatives would enable gradual release of the drug. Use of Lam-
D derivatives having differently protected phenols allowed selective deprotection and 
further conjugation with PEG-carboxylic acids to enable synthesis of mono-PEG (2-5), 
di-PEG (6, 7) and tri-PEG (8, 9) conjugates (Fig. 1). 
The derivatives prepared contain monodisperse PEG backbones with OMe (2, 4, 6, 7, 
8, and 9) and NH2 (3, 5) terminal moieties and vary in their chain length. The PEGs 
used for derivatization contain one, two, or six sequentially linked units of ethylene 
glycol. Another source of diversity introduced in the PEG carriers was a spacer, acetyl 
(2, 4, 6, 7, 8, and 9) or propanoyl (3, 5) moieties were used.  
The methodology developed in our group for the total synthesis of Lam-D (15) was 
used for the preparation of conjugates 2-9. The key steps of the synthesis comprise two 
successive processes of regioselective bromination and Pd(0)-catalyzed cross-coupling 
reactions starting from the scaffold 10. 
As shown in Scheme 1, several dialkoxy and trialkoxy-phenylboronates 11a-b and 
12a-b were required. These compounds were obtained with good yields by borylation of 
the corresponding aryl bromides with pinacolborane using Pd(OAc)2 and DPE-Phos as 
catalysts (for details, see  Supporting Information). The protected alkoxy-aryl bromides 
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required were obtained by protection of commercially available phenols followed by 
mild bromination via NBS in THF at -78 ºC (20). 
Regioselective bromination of 10 (21) at position 1 using one equivalent of NBS in 
THF followed by Pd(0)-catalyzed cross-coupling reaction with the boronic ester 11a or 
11b afforded the monoaryl scaffolds 13a and 13b (15), respectively, which were 
converted into the bromides 14a, 14b (15) by regioselective bromination at position 2. 
A second cross-coupling reaction, using the trialkoxyphenylboronates 12a or 12b, gave 
the diaryl derivatives 15a-c (with the desired orthogonal protected phenol groups as 
iPr/Bn ethers) in 45-64% yields from the scaffold 10.  
Tight control of the oxidation of 15 using 1 equivalent of DDQ and MW irradiation at 
120 ºC for 10 min gave 16a-c (65-93% yield), avoiding the complex mixtures obtained 
by simultaneous O-Bn cleavage using other conditions (22).  
The OBn protecting group was successfully removed to give 17a-c in 70-95% yields 
by hydrogenolysis over Pd-C in methanolic solution. Lactonization in excellent yields 
(86% to quant.) was achieved by direct treatment of the methyl esters 17a-c with 
sodium hydride in THF. Lactonization was needed before PEGylation to protect the 
phenol required in the lactone formation and to prevent undesired PEG removal caused 
by the instability of the ester bond under the basic reaction conditions.2 Compounds 18a 
and 18b, having only one free phenol group (each of which at a distinct position), and 
18c, with two free phenol groups, were then further conjugated. The PEG-groups were 
successfully introduced by esterification of the free phenols of 18a-c to give compounds 
19a-f using EDC·HCl with a catalytic amount of DMAP in CH2Cl2 (23). The same 
reaction conditions were used for the conjugation of Lam-D, obtained by deprotection 
of two isopropyl groups of 18c with AlCl3, to give the triester derivatives 8 and 9. The 
isopropyl-protecting groups of 19a-f were eliminated using AlCl3 in CH2Cl2 with 
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moderate to good yields, with concomitant removal of the N-Boc-protecting groups of 
19b and 19d.  
High polarity solvents such as DMSO and PEG-400 were required to dissolve Lam-D 
(1), which is insoluble in most common solvents. The solubility of monoPEG 
compounds 2-5, with a single conjugation of one phenolic residue, is much better to that 
of Lam-D.3 Conjugate 3, bearing six units of ethylene glycol and a NH2 termination, 
showed 80-fold more solubility in water than Lam-D. The solubility of conjugates 3, 7 
and 9 -mono-, di- and tri-ester, respectively- in PEG-400 solvent was in accordance 
with the increase of PEG conjugations. Final compounds 2-9 were prepared in 18 to 
57% yields from the corresponding phenolic Lam-D precursors.  
Lastly, the conjugates were further evaluated biologically and in vitro drug delivery 
assays were carried out. 
Cytotoxicity and Cellular Uptake. 
The cytotoxicity of Lam-D (1) and its analogs (2-9) was evaluated against BJ human 
skin fibroblasts, and a panel of three human tumor cell lines: HT-29, A-549 and MDA-
MB-231. A conventional colorimetric assay was used to estimate values of GI50 (i.e. the 
drug concentration that causes 50% of cell growth inhibition after 72 h of continuous 
exposure to the test molecule (17)). The results are shown in Table 1. 
Conjugates 2-9 are all active against the cell lines: HT-29, the cytotoxicity of 2-9 is 
similar to that of Lam-D; in A-549 and MDA-MB-231 cell lines, the activity of 2-4 and 
6-9 is 1.4-4.3-fold better than Lam-D. Furthermore, BJ skin fibroblasts were used in the 
present study to evaluate the effects of the drug and its conjugates in normal cells. In 
this non tumoral cellular culture, conjugates 3, 6 and 7 maintained the same order of 
magnitude of cytotoxicities than Lam-D. Besides, conjugates 2, 4, 5, 8, and 9 showed a 
decrease of 4 to 500-fold in their cytotoxic activity for BJ skin fibroblasts.  
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The results of initial cellular internalization experiments in HeLa cells at different 
compound concentrations and exposure times were encouraging for Lam-D and 7 (see 
Fig. SI1 and Fig. SI2 in the Supporting Information). Compound 9 was selected as one 
of the best compounds of the series for co-localization experiments. Cell cultures were 
incubated with compound 9 for 48 h. WGA-FITC and Mitotracker were then employed 
for the selective staining of cell membrane-Golgi apparatus (green fluorescence) and 
mitochondria (red fluorescence), respectively. Likewise, UV fluorescence 
corresponding to 9 was observed in the cytoplasm;4 however, no fluorescence was 
observed in the nuclear region of any of the cells for  compound 9 (Fig. 2). 
The internalization of compounds 1-9 was measured by FACS flow cytometry (see 
Table 2). Conjugates 3, 6 and 9 underwent the greatest cellular uptake in HT-29 and 
MDA-MB-231. Furthermore, conjugates 2-9 all had higher internalization in A-549 
than did Lam-D. Results were normalized in function of Lam-D uptake, thus the CIQ 
was calculated relative to 100% internalization for Lam-D (1). The comparative study 
showed that all the PEG conjugation motifs introduced enabled greater internalization in 
A-549, and BJ cell lines. For compounds 4, 8 and 9, the ratio was greater than 150%. 
Although compounds 3, 6 and 9 exhibited greater internalization than did Lam-D (1) in 
HT-29 and MDA-MB-231, the differences observed for these cell lines were not as 
dramatic. Likewise, as observed in the results for 3, monoconjugation enables greater 
uptake. The introduction of the PEG-NH2 backbone at phenolic position 3 of Lam-D 
(compound 3) led to better GI50 cytotoxicity and internalization than at position 4’ 
(compound 5).  
Effects of 1 on Cell Cycle Progression of HT-29 Cells.  
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Lam-D was tested for effects on cell cycle progression in HT-29 tumor cells (Fig. 3). 
Cells were treated with the product (see Experimental Section) and then analyzed by 
flow cytometry to determine if the cell cycle had been arrested at a specific phase. A 
control set of untreated cells was also used. 
Compared to the control cells (Fig. 3, panels 1a, c), the cells treated with 1 (Fig. 3, 
panels 1b, c) showed an arrest in G2/M progression. Hence, it was concluded that Lam-
D inhibits cell cycle progression. Furthermore, conjugates 3 and 9 provoked cell cycle 
arrest in a greater extent. The results showed one single peak corresponding to the 
G2/M phase (see Fig. SI3 in the Supporting Information). 
Induction of Apoptosis by 1, 3 and 9 in HT-29, A-549, and MDA-MB-231 Cell 
Lines. Many anticancer drugs induce cell cycle arrest and apoptosis. Apoptotic cells 
undergo characteristic morphological changes. Among these, the cell surface often 
bends and breaks up into membrane-enclosed fragments called apoptotic bodies. This 
process depends on a cascade of proteolytic enzymes called caspases (24).  
To analyze whether Lam-D induces apoptosis, HT-29, A-549, and MDA-MB-231 cell 
lines were incubated with a single compound and then qualitatively measured for 
apoptosis (Fig. 4, see Experimental Section). The assay consists of detecting active 
caspases (caspase-3/7) using a commercially available colorimetric test. 
All cell lines showed a high level of apoptotic cell death after treatment with 
compounds 1, 3 and 9 (Fig. 4, panels d−l). A negative control of the assay was 
performed by analyzing untreated cells under the same experimental conditions (Figure 
4, panels a−c). Altogether, these results indicate that Lam-D and derivatives 3 and 9, 
induce cell cycle arrest and apoptosis. 
DISCUSSION 
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A procedure for preparing PEGylated Lam-D pro-drugs has been described for the 
first time. One, two or three phenol groups were selectively conjugated to the Lam-D in 
mild reaction conditions employing selective orthogonal protection (benzyloxy and 
isopropoxy groups).  
The feasibility of the selective modification of the phenolic moieties of Lam-D has 
been demonstrated with readily available and inexpensive PEG-carboxylic acid as 
starting material. Conjugates functionalized with only a single phenolic residue of 2-5 
(C-3 or C-4’ OH groups) are much more soluble than Lam-D in various solvents. 
Notwithstanding, di- and tri-PEG conjugates were also synthesized. Di- and tri-PEG 
conjugates -which imply greater steric hindrance- were also synthesized, thereby 
demonstrating the robustness of our method. The pH-labile ester conjugates were 
prepared in 18 to 57% yields from the corresponding Lam-D phenolic precursors.  
Conjugates (2-9), screened against normal BJ skin fibroblasts and three human cancer 
cell lines, exhibited better internalization than Lam-D (1) did. Conjugation provided 
cytotoxicity amelioration for the cancerous cell lines. Indeed, the GI50 of conjugates 2-4, 
6, 7 and 9 (bearing mono-, di- and tri-PEG backbones) in MDA-MB-231 and A549 
cancer cell lines were one order of magnitude lower than that of Lam-D (1). 
Comparison of cytotoxic activity in BJ skin fibroblast between Lam-D and compounds 
2-9 shown that bioconjugates are equal or less toxic than Lam-D.  Compounds 2, 4, and 
9 with higher cytotoxycity than Lam-D in A-549 and MDA-MB-231 tumor cell lines 
displayed less cytotoxyc-activity in the BJ normal cell line. Although these compounds 
2, 4, and 9 possess better internalization in normal cells. These results indicate that these 
compounds have better affinity to components of tumor cell lines. Confocal microscopy 
revealed that Lam-D (1) and the conjugates (2-9) were internalized in the cytoplasmatic 
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region. Furthermore, Lam-D induces cell cycle arrest at the G2 phase. Lam-D, and 
derivatives 3 and 9, produce caspase-3,7-dependent apoptosis in all cell lines tested. 
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Footnotes: 
 
1
 Abbreviations: AU, absorbance units; A-549, lung carcinoma cell line; BJ, skin 
fibroblast cell line; Bn, benzyl; Boc, tert-butoxycarbonyl; CIQ, cellular internalization 
quotient; DDQ, 2,3-dichloro-5,6-dicyano-p-benzoquinone; DMAP, 4-
dimethylaminopyridine; DMEM, Dulbecco’s modified Eagle’s medium; DMF, 
dimethylformamide; DMSO, dimethylsulfoxide; DPE-Phos, (oxydi-2,1-
phenylene)bis(diphenylphosphine); EDC·HCl, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride; EPR, enhance permeability and retention; FACS, 
fluorescence-activated cell sorting; FBS, fetal bovine serum; FITC, fluorescein 
isothiocyanate; HeLa, human cervix carcinoma cell line; HT-29, colon carcinoma cell 
line; GI50, 50 percent growth inhibition; iPr, isopropyl; Lam, Lamellarin; MDA-MB-
231, breast adenocarcinoma cell line; MW, microwave; NBS, N-bromosuccinimide; 
PBS, phosphate buffered saline; PEG, poly(ethyleneglycol); PEGylated, 
polyethyleneglycolated; SAR, structure activity relationship; SRB, sulforhodamine B; 
WGA, wheat germ agglutinin; THF, tetrahydrofurane; Topo, topoisomerase. 
 
2
 Lactonization of methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-8-hydroxy-1-(4-(2-(2-(2-
methoxyethoxy)ethoxy)acetoxy)-3-methoxyphenyl)-9-methoxypyrrolo[2,1-
a]isoquinoline-3-carboxylate did not provide compound 4; rather, it led exclusively to 
formation of Lam-D. 
 
3
 The conjugates are more soluble in water, EtOH and PEG-400 than is Lam-D. See 
Table SI1 in the Supporting Information. 
 
4
 The Lam-D UV spectrum presents four characteristic absorption maxima: 237, 267, 
356 and 382 nm. Excitation at 267 nm of 1 led to three emission maximum wavelengths 
(319, 430 and 490 nm). The authors assumed that any minor deviation in the molar 
extinction coefficient of 2-9 due to ester conjugation of 1 with aliphatic PEG backbones 
was not important. 
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Table 1. Cytotoxicity of compounds 1-9 in three human cancer cell lines.  
Compound 
Cytotoxicity (M) 
HT-29 Colon A-549 Lung MDA-MB-231 Breast 
BJ Skin 
Fibroblast 
Lam-D (1) 3.00 10-6 1.22 10-7 1.34 10-7 6.37 10-9 
2 1.97 10-6 7.13 10-8 4.55 10-8 6.28 10-7 
3 1.68 10-6 8.86 10-8 4.07 10-8 6.51 10-9 
4 1.97 10-6 5.46 10-8 5.31 10-8 2.90 10-6 
5 4.79 10-6 3.47 10-7 2.52 10-7 3.51 10-6 
6 1.28 10-6 6.29 10-8 3.14 10-8 1.81 10-9 
7 5.49 10-6 5.37 10-8 7.68 10-8 3.17 10-9 
8 4.60 10-6 7.31 10-8 1.04 10-7 4.90 10-8 
9 4.08 10-6 4.69 10-8 8.57 10-8 2.67 10-8 
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Table 2. Cellular internalization uptake measured by FACS.  
Compound 
Cellular Internalization Uptake (AU) Cellular Internalization Quotient (CIQ)a 
HT-29 
Colon 
A-549 
Lung 
MDA-MB-
231 Breast 
BJ Skin 
Fibroblast 
HT-29 
Colon 
A-549 
Lung 
MDA-
MB-231 
Breast 
BJ Skin 
Fibroblast 
Lam-D 
(1) 
82.7 328.5 443.8 259.4 100%a 100%a 100%a 100%a 
2 41.1 463.1 266.6 321.0 50% 141% 60% 123.8% 
3 88.0 393.0 527.5 333.4 106% 120% 119% 128.6% 
4 59.8 500.6 364.8 501.5 72% 152% 82% 193.4% 
5 84.4 373.7 328.1 371.4 102% 114% 74% 143.2% 
6 90.3 407.2 535.0 317.7 109% 124% 121% 122.5% 
7 49.3 379.3 432.1 279.3 60% 116% 97% 107.7% 
8 78.7 532.6 414.8 352.0 95% 162% 94% 135.7% 
9 143.3 514.8 529.7 371.0 173% 157% 119% 143.0% 
a
 The CIQ has been calculated in reference to the cellular uptake of Lam-D. 
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Chart 1. Cellular internalization quotient. 
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Scheme 1 
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Figure 1. Structures of Lam-D 1 and PEG derivatives 2-9 
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Figure 2. Cellular uptake of 9 and selective staining of mitochondria, Golgi apparatus 
and cell membrane.  
 
 
The following cancer cell lines were used for the co-localization experiments. a) HT-29, 
b) A-549 and c) MDA-MB-231 
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Figure 3. Cell cycle progression of Lam-D in HT-29 cancer cell line. 
 
 
a) HT-29 asynchronous colon cell line; b) HT-29 with 1 µM Lam-D for 12 h.
c) Phase of 
Cell Cycle 
control Lam-D 
G1 (%) 34.8 31.9 
G2/M (%) 12.5 52.2 
S (%) 52.6 15.9 
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Figure 4. Detection of apoptosis by CaspaTag green fluorescence. 
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